Tuesday, March 28, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

NIH Offers Free Chemical Agent Neurotherapeutics Screening Resource

by Global Biodefense Staff
September 27, 2015
NIH CounterACT Chemical Countermeasure Program

The National Institute of Health (NIH) is offering a free resource to the medical countermeasure research and development community via a new CounterACT Neurotherapeutics Screening (CNS) Program.

The purpose of the CNS program is to help provide applicants with important pre-application proof-of-concept efficacy data in support of a research proposals to the CounterACT or other federally-funded peer-reviewed grant program.

The overall goal of the effort is to accelerate the research and development of novel medical countermeasures for organophosphorus chemical threats that target the central nervous system.

The support is provided via a NIH-supported Department of Defense laboratory equipped to conduct translational research on the efficacy of compounds against the lethal and non-lethal effects of OP chemical threat agents in vivo. If accepted for the CNS program, studies are performed at no cost to the investigator/supplier.

The proposed studies must not overlap, but may be conducted in concert with, studies performed within other CounterACT efficacy, preclinical, grant programs. Participants will retain custody of and have primary rights to the data developed, subject to Government rights of access consistent with current U.S. Government policies.

The CNS program is available to U.S. investigators inside and outside of the CounterACT network with promising medical countermeasures for chemical threats. For more information, please contact Dave Yeung, Ph.D., Project Manager, CounterACT Program.

Read more: CounterACT Neurotherapeutics Screening (.pdf)

Tags: AntitoxinsNIH

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC